Our Technology

Filament Health’s wholly owned subsidiary Psilo Scientific Ltd. operates one of the first GMP facilities in the world to also have a Health Canada Dealer’s License. Here we propagate psychedelic plants, conduct genetic research, perform extraction procedures, run in-house trials, and distribute IP, and drug candidates. Our research program includes all controlled natural psychedelics: DMT, harmaline, mescaline, and more.

GMP Facility with Health Canada Dealer's License

These certifications enable Psilo Scientific to supply in-house trials, and distribute IP and drug candidates to drug developers, researchers, and other licensed parties.
3,500 ft2 manufacturing, research, and development facility on BCIT campus
Propagation, extraction, production, distribution and sale
Ongoing propagation and cultivation research program to identify best strains and genetics

Drug Development Platform

Unlike synthetic drugs, which can have thousands of variations, there are few effective ways to extract and purify the compounds in plants.

Filament Health’s drug development platform has led to the discovery of important methods of natural extraction and purification, and we believe that there is potential for many new natural psychedelic medicines to become available in the near term.

Natural Psychedelic Processing Steps

01.

Propagation

Grow botanical psychedelics

02.

Extraction

Remove target compounds from biomass

03.

Purification

Remove undesirable elements

04.

Standardization

Exact concentrations

05.

Distribution

Different methods and forms

Our Clinical Trials

One platform, many trials.

Filament’s comprehensive platform offers the potential for hundreds of drugs to be discovered and run through our own clinical trials or in partnership with other companies.

Two of Filament’s unique patent-protected drug candidates will enter two separate FDA investigator-initiated human clinical trials in 2021.

Drug Candidates Description Status
Phase 1 Trial
PEXO10
PEX020
PEX030
First-ever direct administration of psilocin with IP-protected PEX020 (Oral) and PEX030 (Sublingual); measuring therapeutic effects directly against PEX 010 (Oral Psilocybin 25mg)
FDA Authorization Received Q4 2021
Phase 2 Trial
PEX010
Safety and efficacy PEX010 in Major Depressive Disorder while employing a novel control condition to set a new research standard and overcome a major clinical deficiency.1
Anticipated FDA Authorization Q4 2021

The Filament Health Patent Family

Patent Family at a Glance

Patent Family Deeper Dive

1. Patents held in Filament’s wholly-owned subsidiary, Psilo Scientific.